跳至主要内容
临床试验/NCT01565967
NCT01565967已完成不适用

Registry AutoLog Lipid Removal and Blood Component Characterization

Medtronic Bakken Research Center6 个研究点 分布在 6 个国家目标入组 199 人开始时间: 2011年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
199
试验地点
6
主要终点
level of reduction of nonemulsified fat

研究概览

简要总结

The purpose of this study is to show the success of the AutoLog System in removing lipids to less than 10mg/dl in vivo. The Autolog registry has two objectives:

  1. to determine the lipid removal capabilities of the Medtronic AutoLog System.
  2. to obtain in vivo data on blood component removal and washing capabilities of the Medtronic AutoLog System.

详细描述

Since the in house data strongly suggest that the Medtronic AutoLog is uniquely high performing in lipid removal in-vitro, the Registry AutoLog Lipid Removal and Blood Component Characterization is initiated to determine if the AutoLog system is successful in removing lipids in vivo as it is in-vitro. Therefore, it is expected that the lipid amounts after washing will be less than 10 mg/dl.

The study is designed as a multi-center, non-randomized, non-interventional, post market release study (a registry). The study has a single arm, without controls, as it is descriptive in nature.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with an indication for surgery procedures in which the hospital treatment protocol requires the routine use of an autotransfusion system are eligible for participation.

排除标准

  • The use of citrate-based anticoagulant in patients with impaired liver function
  • Gross contamination and/or septic procedures
  • Surgery within the malignant area that may allow dissemination of tumor/malignant cells, if aspirated, into the autotransfusion system
  • Caesarean sections in presence of amniotic fluid
  • Presence of high concentrations of prostatic fluid
  • Contamination of salvaged blood with drugs not intended for intravenous administration
  • Use of collagen-based haemostatic agents and gel foam used in combination with any autotransfusion system
  • Coagulopathy
  • Not willing to sign a Patient Informed Consent/Data Release Form

结局指标

主要结局

level of reduction of nonemulsified fat

时间窗: after process

The primary endpoint of this study is the level of reduction of nonemulsified fat after processing through the Medtronic AutoLog.

次要结局

未报告次要终点

研究者

发起方
Medtronic Bakken Research Center
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验